IT1271593B - Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120. - Google Patents

Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.

Info

Publication number
IT1271593B
IT1271593B ITVR940096A ITVR940096A IT1271593B IT 1271593 B IT1271593 B IT 1271593B IT VR940096 A ITVR940096 A IT VR940096A IT VR940096 A ITVR940096 A IT VR940096A IT 1271593 B IT1271593 B IT 1271593B
Authority
IT
Italy
Prior art keywords
antibodies
protein
pathogenic factors
hiv virus
specific
Prior art date
Application number
ITVR940096A
Other languages
English (en)
Inventor
Alessandro Zuccato
Original Assignee
Sanitaria Scaligera Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitaria Scaligera Spa filed Critical Sanitaria Scaligera Spa
Publication of ITVR940096A0 publication Critical patent/ITVR940096A0/it
Priority to ITVR940096A priority Critical patent/IT1271593B/it
Priority to PCT/IT1995/000206 priority patent/WO1996016666A1/en
Priority to DE69531069T priority patent/DE69531069T2/de
Priority to AU41864/96A priority patent/AU4186496A/en
Priority to JP08518558A priority patent/JP2000516193A/ja
Priority to AT95940399T priority patent/ATE242637T1/de
Priority to EP95940399A priority patent/EP0954325B1/en
Priority to ES95940399T priority patent/ES2201125T3/es
Publication of ITVR940096A1 publication Critical patent/ITVR940096A1/it
Application granted granted Critical
Publication of IT1271593B publication Critical patent/IT1271593B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITVR940096A 1994-11-30 1994-11-30 Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120. IT1271593B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ITVR940096A IT1271593B (it) 1994-11-30 1994-11-30 Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
JP08518558A JP2000516193A (ja) 1994-11-30 1995-11-30 エイズ（ａｉｄｓ）の治療において選択された病原性因子類を特異的に免疫吸着するためのモジュール
DE69531069T DE69531069T2 (de) 1994-11-30 1995-11-30 Verfahren zur spezifischen immunabsorption von selektierten pathogenen faktoren zur behandlung von aids
AU41864/96A AU4186496A (en) 1994-11-30 1995-11-30 Method for the specific immunoadsorption of selected pathogenic factors
PCT/IT1995/000206 WO1996016666A1 (en) 1994-11-30 1995-11-30 Method for the specific immunoadsorption of selected pathogenic factors
AT95940399T ATE242637T1 (de) 1994-11-30 1995-11-30 Verfahren zur spezifischen immunabsorption von selektierten pathogenen faktoren zur behandlung von aids
EP95940399A EP0954325B1 (en) 1994-11-30 1995-11-30 Method for the specific immunoadsorption of selected pathogenic factors in the treatment of aids
ES95940399T ES2201125T3 (es) 1994-11-30 1995-11-30 Metodo para inmunoadsorcion especifica de factores patogenos seleccionados para el tratamiento del sida.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITVR940096A IT1271593B (it) 1994-11-30 1994-11-30 Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.

Publications (3)

Publication Number Publication Date
ITVR940096A0 ITVR940096A0 (it) 1994-11-30
ITVR940096A1 ITVR940096A1 (it) 1996-05-30
IT1271593B true IT1271593B (it) 1997-06-04

Family

ID=11427924

Family Applications (1)

Application Number Title Priority Date Filing Date
ITVR940096A IT1271593B (it) 1994-11-30 1994-11-30 Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.

Country Status (8)

Country Link
EP (1) EP0954325B1 (it)
JP (1) JP2000516193A (it)
AT (1) ATE242637T1 (it)
AU (1) AU4186496A (it)
DE (1) DE69531069T2 (it)
ES (1) ES2201125T3 (it)
IT (1) IT1271593B (it)
WO (1) WO1996016666A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912188B1 (de) * 1996-07-12 2003-01-29 Imtec Immundiagnostika Gmbh Selektives adsorbens zur bindung von retroviren
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
MX2007003522A (es) 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US9241977B2 (en) 2013-03-01 2016-01-26 Arthrex, Inc. Enhanced anabolic cytokine production and delivery system
DE102016106510A1 (de) * 2016-04-08 2017-10-12 ToposNomos Ltd. Verfahren und Vorrichtung zum extrakorporalen Entfernen von pathogenen und/oder überzähligen Bestandteilen aus einer Zellprobe eines Patienten
CN106267414B (zh) * 2016-07-01 2019-02-19 翁炳焕 艾滋病免疫净化器
CN106267416B (zh) * 2016-07-01 2019-02-19 翁炳焕 艾滋病治疗仪
FR3109734A1 (fr) 2020-05-04 2021-11-05 Mexbrain Système de dialyse pour le traitement du sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1536425A (en) * 1976-01-30 1978-12-20 Nat Res Dev Blood treatment
JPH0218858B2 (it) * 1979-06-11 1990-04-26 Gambro Lundia Ab
JPS57103649A (en) * 1980-12-18 1982-06-28 Asahi Chemical Ind Sterilized gamma-globulin fixing column
EP0103184B1 (en) * 1982-08-12 1990-01-17 Kanegafuchi Chemical Industry Co., Ltd. Activation of biocompatible terpolymers with biologicals whose binding complements are pathological effectors
US5037649A (en) * 1985-01-11 1991-08-06 Imre Corporation Method for treatment of HIV-infected patients
DE3854857T2 (de) * 1987-06-10 1996-08-22 The Immune Response Corp. Inc., La Jolla, Calif. Verhütung und behandlung einer retrovirenkrankheit
US4831118A (en) * 1987-08-07 1989-05-16 Scripps Clinic And Research Foundation Flouroplastic immunoaffinity columns for purification of blood proteins
CZ289006B6 (cs) * 1990-11-08 2001-10-17 Chiron Corporation Asialoglykoprotein hepatitis C viru, farmaceutická kompozice s jeho obsahem a jeho pouľití
US5223397A (en) * 1991-06-05 1993-06-29 Sangstat Medical Corporation Soluble hla cross-match
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
JP3331398B2 (ja) * 1993-05-28 2002-10-07 バクスター、インターナショナル、インコーポレイテッド 不均質な細胞混合物から特定の細胞集団を分離するための方法、装置およびシステム

Also Published As

Publication number Publication date
WO1996016666A1 (en) 1996-06-06
DE69531069D1 (de) 2003-07-17
EP0954325B1 (en) 2003-06-11
ES2201125T3 (es) 2004-03-16
JP2000516193A (ja) 2000-12-05
ATE242637T1 (de) 2003-06-15
DE69531069T2 (de) 2004-05-06
EP0954325A1 (en) 1999-11-10
AU4186496A (en) 1996-06-19
ITVR940096A0 (it) 1994-11-30
ITVR940096A1 (it) 1996-05-30

Similar Documents

Publication Publication Date Title
EP0308936B1 (en) Antibody heteroconjugates for the killing of HIV-infected cells
Stricker et al. An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells
Robinson Jr et al. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro
Bettaieb et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura
Takeda et al. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R
IT1271593B (it) Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
DE69126301D1 (de) Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
Cavacini et al. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals
US5286852A (en) Antibodies specific towards HIV-1 gp 48
Alsmadi et al. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
Pak-Leong Isolation of specific IgM monoclonal antibodies by affinity chromatography using alkaline buffers
Tomiyama et al. Recognition of human immunodeficiency virus glycoproteins by natural anti-carbohydrate antibodies in human serum
US5658569A (en) Anti-HIV-1 neutralizing antibodies
Lundin et al. A specific assay measuring binding of 125I-Gp 120 from HIV to T4+/CD4+ cells
MATSUSHITA et al. Selective killing of HIV-infected cells by anti-gp120 immunotoxins
Chams et al. Biological properties of anti-CD4 autoantibodies purified from HIV-infected patients
Chen et al. HIV-1 gp4l Binding to Human Peripheral Blood Mononuclear Cells Occurs Preferentially to B Lymphocytes and Monocytes
Lewis et al. HLA-DR peptide inhibits HIV-induced syncytia
Biberfeld et al. Antibodies to Surface Antigens of Lymphocytes and Lymphoblastoid Cells in Cold‐Agglutinin‐Positive Sera from Patients with Mycoplasma pneutnoniae Infection
EP0511300A1 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
Chen et al. HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells
Good et al. In vitro immunomodulation and in vivo immunotherapy of retrovirus-induced immunosuppression
Hattori et al. Anti-HTLV-III and anti-HTLV-I antibodies and T cell subsets in hemophiliacs living in HTLV-I endemic and nonendemic areas of Japan
Miller et al. CD4-independent inhibition of lymphocyte proliferation mediated by HIV-1 envelope glycoproteins
US5529776A (en) Anti-HIV-1 neutralizing antibodies

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971130